We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · January 03, 2022

Seviprotimut-L Polyvalent Melanoma Vaccine in Patients With Post-Resection Melanoma

Journal for immunotherapy of cancer

 

Additional Info

Journal for immunotherapy of cancer
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
J Immunother Cancer 2021 Oct 01;9(10)e003272, CL Slingluff, KD Lewis, R Andtbacka, J Hyngstrom, M Milhem, SN Markovic, T Bowles, O Hamid, L Hernandez-Aya, J Claveau, S Jang, P Philips, SG Holtan, MF Shaheen, B Curti, W Schmidt, MO Butler, J Paramo, J Lutzky, A Padmanabhan, S Thomas, D Milton, A Pecora, T Sato, E Hsueh, S Badarinath, J Keech, S Kalmadi, P Kumar, R Weber, E Levine, A Berger, A Bar, JT Beck, JB Travers, C Mihalcioiu, B Gastman, P Beitsch, S Rapisuwon, J Glaspy, EC McCarron, V Gupta, D Behl, B Blumenstein, JJ Peterkin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading